Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Owens Rebecca Anne"'
Autor:
Jamie L. Blackbourne, David E. Coutant, Julie S. Moyers, Owens Rebecca Anne, M. Dodson Michael, Richard A. Byrd, A. Eric Schultze, John L. Vahle, Michael K. Sievert, Niraj Tripathi, Mark W. Farmen
Publikováno v:
Regulatory Toxicology and Pharmacology. 88:56-65
Basaglar®/Abasaglar® (Lilly insulin glargine [LY IGlar]) is a long-acting human insulin analogue drug product granted marketing authorisation as a biosimilar to Lantus® (Sanofi insulin glargine [SA IGlar]) by the European Medicines Agency. We asse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da1e31f53c987023a1ffe89a88e5134b
https://doi.org/10.1016/j.yrtph.2017.05.013
https://doi.org/10.1016/j.yrtph.2017.05.013
Autor:
John Michael Beals, Hui-Rong Qian, Steven D. Kahl, Xiaoping Ruan, Gordon B. Cutler, Andrew Mark Vick, Owens Rebecca Anne, Julie S. Moyers, Mark W. Farmen, M. Dodson Michael, Shun Li, Ryan John Hansen, Chen Zhang, Anja Koester
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 357:459-465
The aim of this research was to characterize the in vivo and in vitro properties of basal insulin peglispro (BIL), a new basal insulin, wherein insulin lispro was derivatized through the covalent and site-specific attachment of a 20-kDa polyethylene-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05c2025f98992771961b7f38e68e34dd
https://doi.org/10.1124/jpet.115.231035
https://doi.org/10.1124/jpet.115.231035
Autor:
Julie S. Moyers, Steven D. Kahl, M. Dodson, Chen Zhang, Xiaoping Ruan, I. Benabbad, Owens Rebecca Anne, Mark W. Farmen
Publikováno v:
Diabetes & Metabolism. 42:A40
Introduction Les analogues de l'insuline basale sont importants pour un controle glycemique correct des patients diabetiques. LY IGlar est un nouvel analogue de l'insuline, avec la meme sequence d'amino-acides que l'insuline glargine (Sanofi-Aventis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53a7a7d78aedf3ef0198ba19df9a0ec2
https://doi.org/10.1016/s1262-3636(16)30151-3
https://doi.org/10.1016/s1262-3636(16)30151-3
Autor:
Lisa Janine Hammond, Julie S. Moyers, De Shan Li, Farrokh Mehrbod, Armen B. Shanafelt, Jesper Gromada, Eric D. Hawkins, S. Richard Jaskunas, Anja Koester, Amy M. Ford, Elizabeth Galbreath, Radmila Micanovic, Tatiyana L. Shiyanova, Joseph T. Brozinick, George E. Sandusky, Alexei Kharitonenkov, Owens Rebecca Anne, Victor J. Wroblewski
Publikováno v:
The Journal of clinical investigation. 115(6)
Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da01a0327a212a2cf90125bc97407a42
https://pubmed.ncbi.nlm.nih.gov/15902306
https://pubmed.ncbi.nlm.nih.gov/15902306
Autor:
Philip W. Iversen, Thomas A. Engler, Daniel A. Briere, Eric D. Hawkins, Michael P. Clay, YiHong Burlingame Li, Queener S, O'toole John Cunningham, Robert M. Campbell, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Elizabeth A. Misener, Jon K. Reel, Terry D. Lindstrom, Warren J. Porter, Vaughn R, Brian Eugene Cunningham, Henry, Richard A. Brier, Kelly Wayne Furness, Sushant Malhotra, Burkholder Timothy P, Joseph T. Brozinick, Owens Rebecca Anne, Angela Lynn Marquart, David Mendel, Thomas E Eessalu, Wagner, Mclean Johnathan Alexander
Publikováno v:
Journal of medicinal chemistry. 47(16)
Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00fe6d62503568cadbbd9dbb210bf4f3
https://pubmed.ncbi.nlm.nih.gov/15267232
https://pubmed.ncbi.nlm.nih.gov/15267232
Autor:
David Monteith, Brian R. Berridge, Sanjay Bhanot, Aaron D. Showalter, Kyle W. Sloop, Julie S. Moyers, Lynnetta Watts, Robert Mckay, Martin B. Brenner, Achim Raap, M. Dodson Michael, Brett P. Monia, Amy L. Cox, Diane M. Bodenmiller, Owens Rebecca Anne, Julia Xiao-Chun Cao, Hong Yan Zhang, Niels Pørksen, Steven J. Jacobs, Angela M. Siesky, Jesper Gromada
Publikováno v:
The Journal of clinical investigation. 113(11)
Uncontrolled hepatic glucose production contributes significantly to hyperglycemia in patients with type 2 diabetes. Hyperglucagonemia is implicated in the etiology of this condition; however, effective therapies to block glucagon signaling and there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79cca7d0fd54ce6e84c266e987effdec
https://pubmed.ncbi.nlm.nih.gov/15173883
https://pubmed.ncbi.nlm.nih.gov/15173883